Cortagen vs Livagen

Brain cortex-derived tetrapeptide that modulates gene expression in neural and cardiac tissue through chromatin regulatory mechanisms; microarray analysis demonstrates broad transcriptional effects following administration.

Cortagen is a synthetic tetrapeptide (Ala-Glu-Asp-Pro) classified as a Khavinson-class bioregulator derived from cerebral cortex tissue, investigated for gene expression regulatory effects in neural and cardiac tissue. As a Khavinson-class bioregulator, cortagen is proposed to modulate transcriptional activity in aging target tissue by interacting with gene regulatory elements; microarray analysis of cardiac gene expression following cortagen administration has demonstrated broad effects on transcriptional profiles across multiple functional gene categories, suggesting tissue-regulatory activity beyond its cortical tissue origin. Published research on Khavinson-class peptides has further characterized the systematic gene expression regulatory potential of short bioregulator peptides across tissue types, providing the mechanistic context within which cortagen's transcriptional effects are interpreted. Cortagen has no FDA approval or regulatory approval in any major Western jurisdiction; evidence derives from Khavinson-series preclinical studies with no independent clinical trials published in Western-indexed journals. Cortagen benefits investigated in preclinical research include neuroprotective effects in neural tissue, cardiovascular gene expression modulation, and support for vascular wall integrity in aged animal models. As a brain cortex-derived Khavinson bioregulator, cortagen is proposed to regulate transcription in neural and cardiac tissue through chromatin-level mechanisms, potentially preserving tissue-specific gene expression patterns that decline with aging. Research interest encompasses cortagen's role in neurological aging, post-ischemic brain tissue recovery in preclinical models, and combined bioregulator protocols that pair cortagen with cardiovascular and metabolic peptides for comprehensive longevity applications. Cortagen is a research compound with no regulatory approval in any jurisdiction; evidence is limited to preclinical studies and Russian clinical research literature, with no independent randomized trials published in Western peer-reviewed journals.

Tetrapeptide bioregulator for hepatocytes; activates gene expression in liver cells; promotes liver cell regeneration; restores lymphocyte activity via liver-mediated immune pathways

Livagen is a synthetic tetrapeptide classified as a Khavinson-class bioregulator targeted at liver and hepatocyte tissue, investigated for cytoprotective and anti-aging effects on hepatocellular gene expression and chromatin organization through proposed regulatory mechanisms analogous to other short Khavinson-class bioregulators. Like other Khavinson bioregulator peptides, livagen is proposed to modulate gene expression in target hepatocyte cells through epigenetic and transcriptional mechanisms, with tissue-specific targeting proposed to support hepatocyte function and liver regenerative capacity under conditions of aging-related cellular stress. Published research on Khavinson-class ultrashort peptides has characterized neuroepigenetic mechanisms of action in aging tissue models and demonstrated peptide regulation of cell differentiation in progenitor populations, providing the class-level mechanistic context for livagen's proposed hepatic regulatory effects. Livagen has no FDA approval or regulatory approval in any major Western jurisdiction; evidence derives entirely from Khavinson-series preclinical and class-level studies with no independent clinical trials published in Western-indexed journals.